Valdemar Priebe

Via Francesco Chiesa 5
Bellinzona, TI 6500, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia.

TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia.

Journal: Science advances

Published: May 06, 2026

ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells.

ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells.

Journal: British journal of haematology

Published: December 12, 2022

The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG.

The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG.

Journal: Nature communications

Published: March 07, 2022

ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.

ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 23, 2021

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.

Journal: Blood advances

Published: October 08, 2020

Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.

Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.

Journal: Cancers

Published: June 23, 2020

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.

Journal: Blood advances

Published: March 16, 2020

Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.

Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.

Journal: British journal of haematology

Published: March 10, 2019

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

Journal: Haematologica

Published: January 26, 2019

Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.

Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.

Journal: Leukemia

Published: October 10, 2018

The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.

The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 20, 2018

The transcription factor ETS1 in lymphomas: friend or foe?

The transcription factor ETS1 in lymphomas: friend or foe?

Journal: Leukemia & lymphoma

Published: November 04, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026